Pulmonary alveolar proteinosis is a rare diffuse lung syndrome (prevalence 7–27 per million) characterized by accumulation of lipoproteinaceous surfactant material within the alveoli, leading to progressive hypoxemic respiratory insufficiency. [1-2] Autoimmune PAP (aPAP) accounts for >90% of cases and is driven by neutralizing autoantibodies against granulocyte-macrophage colony-stimulating factor (GM-CSF), which impair alveolar macrophage surfactant clearance. [1][3]
The following figure illustrates the pathophysiology of normal surfactant homeostasis versus the disrupted alveolar environment in autoimmune PAP:
1. History
- Key HPI: Progressive dyspnea of insidious onset (weeks to months), often in a previously healthy adult aged 30–50 years [1][5]
- Symptom characterization: Exertional dyspnea is the cardinal symptom; dry cough or production of scant white, frothy sputum [1]
- Timing/progression: Gradual onset over months to years; variable natural history — some patients stabilize, ~20% may spontaneously remit, others progress to respiratory failure [5-6]
- Associated symptoms: Fatigue, weight loss, chest heaviness; rarely pleuritic chest pain
- Important negatives: Digital clubbing, fever, and hemoptysis are not typical of PAP itself — fever and hemoptysis suggest superimposed infection [1]
- Commonly misdiagnosed as community-acquired pneumonia due to nonspecific symptoms and radiographic findings, leading to substantial diagnostic delay [1]
2. Alarm Features
- Acute respiratory failure — especially in the setting of superimposed infection (Nocardia, NTM, Aspergillus, Cryptococcus, Mucor) [1][7]
- Fever or hemoptysis — suggest intercurrent opportunistic infection due to innate immune deficiency from impaired macrophage function [1]
- Rapidly progressive dyspnea in a patient with known hematologic malignancy or myelodysplastic syndrome (secondary PAP) [7]
- Pulmonary fibrosis on imaging — develops in up to 20% and portends poor prognosis [7-8]
- Pleural effusion or mediastinal lymphadenopathy — atypical for PAP and should prompt evaluation for alternative or concomitant diagnosis [8]
3. Medications
- Inhaled GM-CSF (molgramostim or sargramostim): Now considered first-line pharmacotherapy for symptomatic autoimmune PAP per ERS guidelines, following positive results from the IMPALA and IMPALA-2 phase 3 trials [3][9]
- Whole lung lavage (WLL): Remains preferred for patients presenting with respiratory failure or as rescue therapy [9-10]
- Rituximab: Third-line therapy for refractory autoimmune PAP [9]
- Plasmapheresis: Fourth-line option [9]
- Emerging therapies: Statins and PPARγ agonists targeting cholesterol homeostasis in alveolar macrophages are under investigation [9][11]
- No specific contraindicated medications, but immunosuppressants should be used cautiously given the inherent innate immune deficiency in PAP
4. Diet
- No specific dietary triggers or restrictions are established for PAP
- General nutritional optimization is important, as chronic hypoxemia and respiratory insufficiency can lead to weight loss and deconditioning
- Adequate hydration supports mucociliary clearance
5. Review of Systems
- Pulmonary: Dyspnea (exertional → resting), cough, sputum character, exercise tolerance
- Infectious: Fever, night sweats, weight loss (screen for opportunistic infections — Nocardia, NTM, fungal) [1][7]
- Hematologic: Fatigue, easy bruising, recurrent infections (screen for underlying MDS or hematologic malignancy in secondary PAP) [7]
- Constitutional: Weight loss, fatigue, functional decline
- Polycythemia symptoms: Headache, dizziness (chronic hypoxemia can cause secondary polycythemia) [12]
6. Collateral History and Family History
- Occupational/inhalational exposure: Silica, aluminum, titanium, indium-tin oxide, cement dust — can cause secondary PAP or silicoproteinosis [7][13]
- Smoking history: PAP is more prevalent in smokers [2]
- Hematologic history: Prior MDS, leukemia, or hematopoietic cell transplant [7]
- Family history: Hereditary PAP (rare) caused by mutations in CSF2RA or CSF2RB (GM-CSF receptor subunits); congenital PAP from surfactant gene mutations (SFTPB, SFTPC, ABCA3, NKX2.1) — typically presents in neonates/children [2]
7. Risk Factors
- Smoking — strong association; more prevalent in smokers [2][14]
- Age 30–50 years (peak incidence for autoimmune PAP) [5][7]
- Inhalational exposures: Silica, aluminum, titanium, other inorganic dusts [7]
- Hematologic malignancy/MDS/GATA2 deficiency (secondary PAP) [7]
- Allogeneic hematopoietic cell transplant [7]
- Immunodeficiency states [14]
- Affects all races, sexes, and geographic regions roughly equally [1][5]
8. Differential Diagnosis
The "crazy paving" pattern on CT is characteristic but not pathognomonic. Key differential considerations include: [8][14]
- Pulmonary edema — cardiogenic or noncardiogenic; assess BNP, echocardiography
- Pneumocystis jirovecii pneumonia — especially in immunocompromised; check HIV status, β-D-glucan
- Diffuse alveolar hemorrhage — hemoptysis, dropping hemoglobin, serial BAL increasingly bloody
- Organizing pneumonia (COP) — subacute onset, migratory consolidations
- Acute respiratory distress syndrome (ARDS) — acute onset, identifiable trigger
- Lymphangitic carcinomatosis — known malignancy, nodular septal thickening
- Exogenous lipoid pneumonia — history of oil/mineral oil ingestion; centrilobular nodules and consolidation more common than in PAP [15]
- Sarcoidosis — lymphadenopathy, upper lobe predominance
- Silicoproteinosis — occupational silica exposure; dependent consolidation with calcification rather than crazy paving [16]
9. Past Medical History
- Prior episodes of "recurrent pneumonia" unresponsive to antibiotics (common misdiagnosis) [1]
- History of hematologic disorders (MDS, leukemia, lymphoma)
- Prior bone marrow transplant
- Autoimmune conditions
- Occupational exposure history (mining, sandblasting, construction)
- Prior whole lung lavage procedures and response
10. Physical Exam
- Often remarkably normal despite significant radiographic disease — a hallmark clinical-radiologic dissociation [1]
- Vital signs: Resting or exertional hypoxemia (SpO₂ may be normal at rest in mild disease); tachypnea in advanced cases
- Lung auscultation: May reveal fine inspiratory crackles; often clear
- Cyanosis in advanced disease
- Digital clubbing is NOT typical [1]
- Absence of fever (unless superinfected)
- Signs of polycythemia (plethora) in chronic hypoxemia [12]
11. Lab Studies
- Serum anti-GM-CSF autoantibodies: Diagnostic for autoimmune PAP with 100% sensitivity and 100% specificity — commercially available blood test [1][3][17]
- LDH: Elevated; correlates with disease severity but nonspecific [18]
- Serum biomarkers: CEA, KL-6 (Krebs von den Lungen 6), surfactant proteins A and D, cytokeratin 19 fragment (CYFRA 21-1) — elevated and correlate with severity but are not disease-specific [18-19]
- ABG: Hypoxemia with increased A-a gradient; PaO₂ is a key measure of disease severity and treatment response [6][12]
- CBC: May show polycythemia (secondary to chronic hypoxemia) [12]
- BAL fluid: Characteristically milky and opaque (in advanced disease); PAS-positive eosinophilic extracellular material; foamy macrophages 2–3× normal size [7][9][17]
- Rule out secondary causes: CBC with differential, peripheral smear (MDS/leukemia screen), HIV testing
12. Imaging
- Chest X-ray: Bilateral alveolar infiltrates, classically a "bat-wing" perihilar pattern; can progress to confluent infiltrates [8]
- HRCT (gold standard imaging):
- "Crazy paving" pattern — ground-glass opacities with superimposed inter- and intralobular septal thickening; present in ~83% of autoimmune PAP [8][20]
- Geographic/patchy distribution with subpleural sparing in >80% [7][20]
- Lower lung field predominance in autoimmune PAP [20]
- Atypical findings that should prompt alternative diagnosis: Pleural effusion, mediastinal lymphadenopathy, air trapping, pulmonary nodules [8]
- Fibrosis on CT (7–20%) portends poor prognosis [8]
- Secondary PAP typically shows diffuse GGO without crazy paving [20]
The following figure demonstrates the characteristic BAL and histopathologic findings of PAP:
13. Special Tests
- Bronchoalveolar lavage (BAL): Key diagnostic procedure — milky/opaque fluid; cytology shows PAS-positive material and foamy macrophages; confirms diagnosis without need for biopsy in most cases [7][9]
- Serum GM-CSF autoantibody test: Latex agglutination or ELISA — sensitivity 100%, specificity 98–100% [3][17]
- Serum GM-CSF levels: Low/undetectable in autoimmune PAP; elevated in hereditary PAP (useful for distinguishing subtypes) [18]
- Pulmonary function tests: Restrictive pattern; reduced DLCO (key severity marker); reduced FVC [12][21]
- 6-minute walk test: Assesses functional capacity and treatment response [21]
- Lung biopsy: Generally not necessary per guidelines; reserved for atypical cases [7]
- CT grade scoring: Quantitative assessment of opacification extent for monitoring treatment response [8]
14. ECG
- ECG is not a primary diagnostic tool for PAP
- Consider ECG to evaluate for right heart strain (right axis deviation, P pulmonale, RV hypertrophy) in patients with chronic severe hypoxemia
- Rule out cardiac causes of dyspnea in the initial workup
15. Assessment
- Typical presentation: Insidious progressive dyspnea ± dry cough in a middle-aged adult (often a smoker) with bilateral ground-glass infiltrates on imaging and a striking clinical-radiologic dissociation (minimal exam findings despite extensive radiographic disease) [1]
- Severity stratification: Based on PaO₂, A-a gradient, DLCO, CT extent, and functional capacity (6MWT) [6][12]
- Classification:
- Autoimmune PAP (90%): GM-CSF autoantibody positive [3]
- Secondary PAP: Underlying hematologic disorder, inhalational exposure, or infection [7]
- Congenital/Hereditary PAP: Surfactant gene or GM-CSF receptor mutations [2]
- Complications: Secondary infections (Nocardia, NTM, fungi), pulmonary fibrosis (up to 20%), respiratory failure, death [1][7]
- Spontaneous remission occurs in ~20% of cases [6]
16. Treatment Plan
Initial stabilization
- Supplemental oxygen for hypoxemia
- Evaluate for and treat superimposed infections empirically if febrile
First-line therapy for autoimmune PAP
- Inhaled GM-CSF (molgramostim or sargramostim): ERS guidelines now recommend this as first-line for symptomatic confirmed aPAP. The IMPALA-2 phase 3 trial demonstrated improved pulmonary gas transfer and functional health status with inhaled molgramostim [3][9]
- Whole lung lavage (WLL): Preferred for patients with respiratory failure at diagnosis; performed under general anesthesia with double-lumen ETT and single-lung ventilation; up to 50 L warmed saline instilled per lung; typically staged in two sessions. Discharge typically within 24–48 hours. One-third require repeat WLL within 2–3 years [6][9-10]
Second-line and beyond
- Inhaled GM-CSF post-WLL to prolong remission and reduce recurrence [10]
- Rituximab (third-line) [9]
- Plasmapheresis (fourth-line) [9]
- Lung transplantation for terminal respiratory failure in eligible patients (disease can recur in transplanted lung) [9]
Secondary PAP: Treat the underlying condition (hematologic malignancy, cessation of inhalational exposure) [13][22]
17. Disposition
- Admission criteria: Respiratory failure, severe hypoxemia (resting SpO₂ <88%), need for WLL, suspected superimposed infection requiring IV antibiotics, hemodynamic instability
- Observation: Post-WLL monitoring (typically 24–48 hours) [10]
- Discharge criteria: Stable oxygenation, no evidence of active infection, outpatient follow-up arranged with pulmonology
- Specialist consultation triggers:
- Pulmonology — all cases for diagnostic confirmation and management
- Interventional pulmonology/thoracic surgery — for WLL at an expert center [9]
- Hematology — if secondary PAP suspected (MDS, leukemia)
- Infectious disease — if opportunistic infection identified
18. Follow Up / Return Precautions
- Follow-up timing: Pulmonology follow-up within 2–4 weeks post-diagnosis or post-WLL; serial PFTs, ABGs, and CT imaging to monitor response and recurrence [10]
- Recurrence is common: ~one-third require repeat WLL within 2–3 years; inhaled GM-CSF post-WLL reduces this risk [10]
- Return precautions — instruct patients to seek immediate care for:
- Worsening dyspnea or new oxygen requirement
- Fever, chills, or productive/purulent sputum (high risk for opportunistic infections)
- Hemoptysis
- Chest pain or syncope
- Patient counseling:
- Smoking cessation is essential [2]
- Avoid occupational inhalational exposures [13]
- Disease is treatable and often reversible with appropriate therapy [5]
- Adherence to inhaled GM-CSF therapy if prescribed
- Expected course: Most patients improve significantly with treatment; long-term surveillance is necessary given recurrence risk and potential for fibrosis [5][10]
References
1. Autoimmune Pulmonary Alveolar Proteinosis. — McCarthy C, Carey BC, Trapnell BC. American Journal of Respiratory and Critical Care Medicine. 2022.
2. Pulmonary Alveolar Proteinosis. — Trapnell BC, Nakata K, Bonella F, et al. Nature Reviews. Disease Primers. 2019.
3. Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis. — Trapnell BC, Inoue Y, Bonella F, et al. The New England Journal of Medicine. 2025.
4. GM-CSF in Autoimmune Pulmonary Alveolar Proteinosis. — Seymour JF. The New England Journal of Medicine. 2025.
5. Autoimmune Pulmonary Alveolar Proteinosis (PAP). — Papiris SA, Kallieri M, Zompatori M, et al. Seminars in Respiratory and Critical Care Medicine. 2025.
6. Inhaled GM-CSF for Pulmonary Alveolar Proteinosis. — Tazawa R, Ueda T, Abe M, et al. The New England Journal of Medicine. 2019.
7. Update of the International Multidisciplinary Classification of the Interstitial Pneumonias: An ERS/ATS Statement. — Ryerson CJ, Adegunsoye A, Piciucchi S, et al. The European Respiratory Journal. 2025.
8. Pulmonary Alveolar Proteinosis in Adults: Pathophysiology and Clinical Approach. — Kumar A, Abdelmalak B, Inoue Y, Culver DA. The Lancet. Respiratory Medicine. 2018.
9. Pharmacotherapy for Autoimmune Pulmonary Alveolar Proteinosis. — Jouneau S, Chauvin P, Lederlin M, Painvin B, Kerjouan M. Drugs. 2025.
10. How I Do It: Whole Lung Lavage in Pulmonary Alveolar Proteinosis. — Ataya A, Mathavan A, Mathavan A, Wang TS. Chest. 2025.
11. Assessment of Statin Treatment for Pulmonary Alveolar Proteinosis without Hypercholesterolemia: A 12‐Month Prospective, Longitudinal, and Observational Study. — Shi S, Gui X, Ding J, et al. BioMed Research International. 2022.
12. Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis. — Trapnell BC, Inoue Y, Bonella F, et al. The New England Journal of Medicine. 2020.
13. Spontaneous Resolution in Autoimmune Pulmonary Alveolar Proteinosis: A Case Series. — Sahoo S, Saxena P, Ravi AK, et al. Chest. 2025.
14. From the Archives of the AFIP: Pulmonary Alveolar Proteinosis. — Frazier AA, Franks TJ, Cooke EO, et al. Radiographics : A Review Publication of the Radiological Society of North America, Inc. 2008.
15. Pulmonary Alveolar Proteinosis Versus Exogenous Lipoid Pneumonia Showing Crazy-Paving Pattern: Comparison of Their Clinical Features and High-Resolution CT Findings. — Choi HK, Park CM, Goo JM, Lee HJ. Acta Radiologica. 2010.
16. Comparative Study of Clinical, Pathological and HRCT Findings of Primary Alveolar Proteinosis and Silicoproteinosis. — Souza CA, Marchiori E, Gonçalves LP, et al. European Journal of Radiology. 2012.
17. Pulmonary Alveolar Proteinosis. — Trapnell BC, Whitsett JA, Nakata K. The New England Journal of Medicine. 2003.
18. Pathogenesis-Driven Treatment of Primary Pulmonary Alveolar Proteinosis. — Lettieri S, Bonella F, Marando VA, et al. European Respiratory Review : An Official Journal of the European Respiratory Society. 2024.
19. An Exploratory Study Investigating Biomarkers Associated With Autoimmune Pulmonary Alveolar Proteinosis (aPAP). — Campo I, Meloni F, Gahlemann M, et al. Scientific Reports. 2022.
20. Comparative Study of High-Resolution CT Findings Between Autoimmune and Secondary Pulmonary Alveolar Proteinosis. — Ishii H, Trapnell BC, Tazawa R, et al. Chest. 2009.
21. Efficacy of Whole Lung Lavage in Pulmonary Alveolar Proteinosis: A 20-Year Experience at a Reference Center in Thailand. — Kaenmuang P, Navasakulpong A. Journal of Thoracic Disease. 2021.
22. Pulmonary Alveolar Proteinosis. — Bonella F, Borie R. Clinics in Chest Medicine. 2025.